ArticleScientific reports2025
Chitosan-encapsulated Aloe vera nanoparticles outperform carrier-free forms in enhancing MSCs therapy for amikacin nephrotoxicity.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Advances and perspectives of functional nanomaterials in scavenging reactive oxygen species for acute kidney injury.Bioactive materials · 2026Review
- Dual Anticancer and Antibacterial Applications of Active Particle Aggregates Containing Metal Phthalocyanines in Dark.International journal of molecular sciences · 2026Article
- Chitosan-based nano-encapsulation enhances the anti-diabetic efficacy of Eremina desertorum extract by ameliorating hyperglycemia, oxidative stress, and inflammation in diabetic rats.Journal of materials science. Materials in medicine · 2026Article
- Combatting psoriasis with nanomedicine: gamma-amino butyric acid-chitosan nanoparticles as a targeted anti-psoriatic therapy.Inflammopharmacology · 2026Article
- GGT-triggered self-immolative dexamethasone-oligopeptide prodrug nanoparticles ameliorate hepatic fibrosis via dual anti-inflammatory/immunomodulatory pathways with minimized systemic toxicity.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) induced by nephrotoxic drugs like amikacin remains a clinical challenge, with mesenchymal stem cells (MSCs) showing limited efficacy due to poor survival and engraftment. While Aloe vera extract (AVE) possesses renoprotective properties, its bioactive compounds suffer from low bioavailability and instability. The study developed and characterized two nanoformulations of AVE; carrier-free nanoparticles (AVENPS) and chitosan-encapsulated nanoparticles (AVE-CSNPS), to enhance mesenchymal stem cells (MSCs) therapy for amikacin-induced kidney injury. In vitro bioactivities (antioxidant, anti-inflammatory, anticoagulant, and cytotoxicity) were evaluated for both nanoformulations. For in vivo assessment, amikacin-induced AKI mice received: MSCs alone, MSCs + AVE, MSCs + AVENPS, MSCs + CSNPS or MSCs + AVE-CSNPS. Phytochemical characterization revealed both formulations preserved key bioactive compounds, with AVE-CSNPS showing superior retention of flavonoids and essential minerals. Physicochemical analysis demonstrated AVE-CSNPS had optimal characteristics for drug delivery, including larger hydrodynamic size, higher positive zeta potential, and enhanced stability (PDI < 0.3). In vitro, AVE-CSNPS exhibited significantly stronger antioxidant, anti-inflammatory, and anticoagulant effects compared to AVENPS, while showing lower cytotoxicity. In vivo, the MSCs + AVE-CSNPS combination therapy most effectively restored kidney function, normalized oxidative stress markers and pro-inflammatory cytokines. These results demonstrated chitosan encapsulation significantly enhanced Aloe vera’s therapeutic potential and MSCs synergy, offering a promising nano-enabled strategy for renal regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.